Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

1. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

2. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Evidence-based Synthesis Program Department of Veterans Affairs Health Services Research & Development Service April 2012 Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Prepared for: Department of Veterans Affairs Veterans Health Administration (...) . Warfarin and Newer Oral Anticoagulants: Long-term Prevention and Treatment of Arterial and VTE Evidence-based Synthesis Program PREFACE Quality Enhancement Research Initiative’s (QUERI’s) Evidence-based Synthesis Program (ESP) was established to provide timely and accurate syntheses of targeted healthcare topics of particular importance to Veterans Affairs (V A) managers and policymakers, as they work to improve the health and healthcare of Veterans. The ESP disseminates these reports throughout V

2012 Veterans Affairs Evidence-based Synthesis Program Reports

3. Anticoagulants in non-valvular atrial fibrillation

Anticoagulants in non-valvular atrial fibrillation 2017 www.kce.fgov.be KCE REPORT 279 ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION 2017 www.kce.fgov.be KCE REPORT 279 HEALTH TECHNOLOGY ASSESSMENT ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION HANS VAN BRABANDT, LORENA SAN MIGUEL, NICOLAS FAIRON, BERT VAES, SEVERINE HENRARD, ANELIA BOSHNAKOVA, ROB COOK, ROB DAVIES, ADITI KARNAD, ALAN LOVELL, CECILE DUBOIS COLOPHON Title: Anticoagulants in non-valvular atrial fibrillation Authors: Hans (...) responsibility of the KCE. Publication date: 9 januari 2017 Domain: Health Technology Assessment (HTA) MeSH: atrial fibrillation; anticoagulants; secondary prevention; Belgium; cost-benefit analysis; Practice Patterns, Physicians'; Practice Guidelines as Topic NLM Classification: QV 193 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2016/10.273/101 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce

2017 Belgian Health Care Knowledge Centre

4. Oral anticoagulation with warfarin - 4th edition

Oral anticoagulation with warfarin - 4th edition Guidelines on oral anticoagulation with warfarin – fourth edition - Keeling - 2011 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. guideline Free Access Guidelines on oral anticoagulation with warfarin – fourth edition (...) can be found at . The objective of this guideline is to provide healthcare professionals with clear guidance on the indications for and management of patients on warfarin. This guideline replaces the previous BCSH guidelines on oral anticoagulants ( ; ). 1. Indications for warfarin and recommended target international normalized ratio (INR) This guideline refers to target INRs rather than target ranges, although the target range is generally taken to be within 0·5 of the target, i.e. a target INR

2011 British Committee for Standards in Haematology

5. Peri-Operative Management of Anticoagulation and Antiplatelet Therapy

Peri-Operative Management of Anticoagulation and Antiplatelet Therapy 1 PERI-OPERATIVE MANAGEMENT OF ANTICOAGULATION AND ANTIPLATELET THERAPY A British Society for Haematology Guideline David Keeling 1 , R Campbell Tait 2 , Henry Watson 3 . 1 Oxford University Hospitals NHS Foundation Trust, Oxford, UK, 2 Glasgow Royal Infirmary, Glasgow, UK, 3 Aberdeen Royal Infirmary, Aberdeen, UK. Correspondence: BSH Administrator, British Society for Haematology, 100 White Lion Street, London, N1 9PF,UK. E (...) the issue of perioperative management of patients on direct oral anticoagulants (DOACs) and antiplatelet agents which are becoming frequent clinical queries. This guideline will consider whether and when anticoagulants and antiplatelet agents should be stopped before elective surgery and invasive procedures, when agents can be restarted and how to manage patients on these drugs who require emergency surgery. If an anticoagulant or antiplatelet effect persists haemostasis may be improved by the use

2016 British Committee for Standards in Haematology

6. Management of Patients on Non?Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Management of Patients on Non?Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association e604 March 7, 2017 Circulation. 2017;135:e604–e633. DOI: 10.1161/CIR.0000000000000477 ABSTRACT: Non–vitamin K oral anticoagulants (NOACs) are now widely used as alternatives to warfarin for stroke prevention in atrial fibrillation and management of venous thromboembolism. In clinical practice, there is still widespread (...) , and prescriptions for long-term anticoagulation will climb. Anticoagulated patients are vulnerable to spontane- ous, traumatic and perioperative bleeding. Warfarin is a vitamin K antagonist (VKA) that has been used for decades to prevent and treat arterial and venous thromboem- bolism (VTE). More recently, 4 non–vitamin K antagonist oral anticoagulants (NOACs) have been approved in the United States as alternatives to warfarin for prevention of stroke resulting from nonvalvular AF (NVAF), and prevention

2017 American Heart Association

7. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications Interventional Spine and Pain Procedures in Patients on Anti... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account (...) Procite Reference Manager Save my selection doi: 10.1097/AAP.0000000000000700 CHRONIC AND INTERVENTIONAL PAIN: SPECIAL ARTICLE Free The American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012 survey of meeting attendees showed that existing ASRA anticoagulation guidelines for regional anesthesia were insufficient for their needs. Those surveyed agreed that procedure-specific and patient-specific factors required separate guidelines for pain and spine procedures. In response, a guidelines

2018 American Society of Regional Anesthesia and Pain Medicine

8. The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews

The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews anticoagulation medicines 18 March 2019 Links Download reports (pdf) Evidence Summary Evidence Report The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews. What do we want to know? Anticoagulation drugs are used to prevent and treat irregular heartbeat (atrial fibrillation, AF), and clotting of blood in veins (venous thromboembolism, VTE (...) ). Until recently, warfarin was the only available drug to manage or prevent these conditions. Recently, novel oral anticoagulants (NOACs) have become available for prescription. To bring together current understanding about these treatments, we sought to address broad research questions: What evidence syntheses have been conducted to address the efficacy and safety of UK-approved oral anticoagulant therapy with respect to warfarin, novel oral anticoagulants, genotyping (i.e. using genetic information

2019 EPPI Centre

9. Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? Full Text available with Trip Pro

Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? - CanadiEM Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? In , by Kerstin de Wit October 23, 2018 All the content from the Blood & Clots series can be found . CanMEDS Roles addressed : Expert, health advocate, communicator Case (...) rule which includes the same variables as the CHADS score with a lower age cut-off of 65 (also used in CHADSVASC). There are two ways you can use these sores in the emergency setting. 1. You can use the estimated yearly risk of stroke to inform your patient about the risks and benefits of starting on anticoagulation. Clinical pearl: The simplest way to convert the CHADS2 score into a clinically meaningful concept is (CHADS2 score x 2) = yearly risk of patient having a stroke. For example

2018 CandiEM

10. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical Considerations Full Text available with Trip Pro

Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical Considerations Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical (...) Considerations - Journal of Vascular and Interventional Radiology Email/Username: Password: Remember me Available now: Use your SIR login to access JVIR. Search Terms Search within Search Share this page Access provided by Article in Press Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical Considerations Endorsed

2019 Society of Interventional Radiology

11. Head Injury and patients on Anticoagulation/Antiplatelet Therapies

Head Injury and patients on Anticoagulation/Antiplatelet Therapies Head Injury and patients on anticoagulant or antiplatelet therapy 1 Head Injury and Patients on Anticoagulant/Antiplatelet Therapies Citation Garrubba M. 2017. Head Injury and Patients on Anticoagulant/Antiplatelet Therapies: A Scoping Review. Centre for Clinical Effectiveness, Monash Innovation and Quality, Monash Health, Melbourne, Australia. Executive Summary Background The Centre for Clinical Effectiveness was requested (...) to review the evidence for managing patients who present with mild trauma to the head and are known to be on oral anticoagulant, antiplatelet therapy. Objective The objectives of this scoping review were to determine: A. How anticoagulants or antiplatelet agents should be managed for patients with minor head trauma? B. What is the optimal timing and frequency of Computed Tomography (CT) brain scans in the period following the minor head trauma (e.g. fall) to determine if intracranial bleeding has

2017 Monash Health Evidence Reviews

12. The efficacy and safety of new oral anticoagulants versus warfarin in patients with atrial fibrillation: a update meta-analysis of randomised trials

The efficacy and safety of new oral anticoagulants versus warfarin in patients with atrial fibrillation: a update meta-analysis of randomised trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

13. Anticoagulation

Anticoagulation Top results for anticoagulation - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for anticoagulation The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

14. Anticoagulation - oral

Anticoagulation - oral Anticoagulation - oral - NICE CKS Share Anticoagulation - oral: Summary There are five oral anticoagulants licensed for use in the UK: warfarin, apixaban, dabigatran, edoxaban and rivaroxaban. Apixaban, dabigatran, edoxaban and rivaroxaban are newer anticoagulants which may be prescribed instead of warfarin for people with non-valvular atrial fibrillation (NVAF): Apixaban, dabigatran, edoxaban and rivaroxaban have been approved by the National Institute for Health (...) , regular follow up and monitoring is still required to: Assess compliance. Enquire about the presence of any adverse effect (e.g. bleeding). Assess for the presence of thromboembolic events (e.g. symptoms of stroke, or breathlessness which may suggest a pulmonary embolism). The most common adverse effect of anticoagulants is bleeding; however, while there is an antidote for warfarin, of the new anticoagulants, there is currently only an antidote for dabigatran. Management of a bleeding complication

2019 NICE Clinical Knowledge Summaries

15. Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation

Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend (...) Safety & Emergency Services theme_10_collection theme_10_frontend theme_10_collection theme_10_frontend Sports, Recreation, Arts & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation Effective Date

2015 Clinical Practice Guidelines and Protocols in British Columbia

16. Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

18. Canadian Urological Association guideline: Perioperative thromboprophylaxis and management of anticoagulation

Canadian Urological Association guideline: Perioperative thromboprophylaxis and management of anticoagulation CUAJ • April 2019 • Volume 13, Issue 4 © 2019 Canadian Urological Association 105 CUA GUIDELINE Cite as: Can Urol Assoc J 2019;13(4):105-14. http://dx.doi.org/10.5489/cuaj.5828 Published online December 14, 2018 Supplementary material available at cuaj.ca Introduction Surgery exposes patients to a risk of venous thromboembo- lism (VTE) and bleeding. VTE includes deep vein thrombosis (...) - laxis are considered. The first is prophylaxis used for primary prevention VTE for patients undergoing surgery. The second is management of an anticoagulant or antiplatelet agent used for treatment or as a form of secondary prevention dur - ing the perioperative period. The CUA thromboprophylaxis guideline panel feels that it is important for urologists to be engaged in the discussion and management in each of these situations. The panel recognizes that in many clinical contexts, other specialists

2019 Canadian Urological Association

19. Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants?

Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? TAKE-HOME MESSAGE Older adults have a lower risk of any severity of bleeding (includes both major and minor bleeding) when treated with aspirin or clopidogrel compared to warfarin. However, if minor bleeding is excluded, only the subgroup of patients aged 80 years or older demonstrate a lower risk the of major bleeding with antiplatelet agents. Is the Risk of Bleeding (...) Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? EBEM Commentators Cameron Gettel, MD Elizabeth M. Goldberg, MD, ScM Department of Emergency Medicine Alpert Medical School of Brown University Providence, RI Results Commentary Several systematic reviews have previously shown that the risk of bleeding with long-term treatment with aspirin was lower than with warfarin. 2,3 It is common clinical practice to use antiplatelet agents as alternatives

2018 Annals of Emergency Medicine Systematic Review Snapshots

20. Management of Bleeding in Patients on Oral Anticoagulants

Management of Bleeding in Patients on Oral Anticoagulants EXPERT CONSENSUS DECISION PATHWAY 2017 ACC Expert Consensus Decision PathwayonManagementofBleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways Writing Committee Gordon F. Tomaselli, MD, FACC, Chair Kenneth W. Mahaffey, MD, FACC, Vice Chair Adam Cuker, MD, MS Paul P. Dobesh, PHARMD John U. Doherty, MD, FACC John W. Eikelboom, MBBS Roberta Florido, MD (...) on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2017;70:XXX–XX. Copies: This document is available on the World Wide Web site of the American College of Cardiology (www.acc.org). For copies of this document, please contact Elsevier Inc. Reprint Department via fax (212) 633-3820 or e-mail (reprints@elsevier.com). Permissions: Multiple copies, modi?cation, alteration, enhancement

2017 American College of Cardiology